Longboard Pharmaceuticals to Participate in Upcoming Investor Conferences
Longboard Pharmaceuticals (Nasdaq: LBPH) has announced participation in two significant upcoming conferences. The team will be at the Citi Annual BioPharma Conference on September 7-8, 2022, in Boston, and will also engage in a fireside chat at the H.C. Wainwright Global Investment Conference from September 12-14, 2022, in New York City. The H.C. Wainwright chat is scheduled for September 14 at 2:30 PM ET. Investors can access the presentations via Longboard's website, where they will also be archived for 30 days.
- None.
- None.
SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will participate in the Citi Annual BioPharma Conference, which is taking place September 7-8, 2022, in Boston, MA, and participate in a fireside chat at the H.C. Wainwright Global Investment Conference, which is taking place September 12-14, 2022, in New York City.
Presentation Details:
Title: Citi 17th Annual BioPharma Conference
Details: Hosting investor meetings Thursday, September 8, 2022
Title: H.C. Wainwright 24th Annual Global Investment Conference
Details: Participating in a fireside chat on Wednesday, September 14, at 2:30 PM ET (Kennedy II) and hosting investor meetings Tuesday, September 13 – Wednesday, September 14, 2022
To access a webcast of the H.C. Wainwright presentation, please visit the “Events & Presentations” page within the Investors Relations section of Longboard’s website at https://www.longboardpharma.com/. The fireside chat will be webcast live and archived on the website for at least 30 days following the event.
About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies. Longboard is also evaluating LP659, a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, in development for the potential treatment of multiple neurological diseases, and LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist, in development for the potential treatment of central nervous system (CNS) diseases and disorders.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Longboard’s participation in the upcoming conferences, Longboard’s clinical and preclinical programs, ability to develop and deliver medicines, and focus. For such statements, Longboard claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Longboard’s expectations. Factors that could cause actual results to differ materially from those stated or implied by Longboard’s forward-looking statements are disclosed in Longboard’s filings with the Securities and Exchange Commission (SEC). These forward-looking statements represent Longboard’s judgment as of the time of this release. Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
FAQ
When is Longboard Pharmaceuticals participating in the 2022 Citi Annual BioPharma Conference?
What is the schedule for the H.C. Wainwright Global Investment Conference for Longboard Pharmaceuticals?
How can I access the presentations from Longboard Pharmaceuticals' conferences?
What is the ticker symbol for Longboard Pharmaceuticals?
What type of company is Longboard Pharmaceuticals?
